Ensign Group (ENSG)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
$171.76+0.72%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Revenue reaches about $5.83 billion in FY 2026: FY26 revenue guidance $5.89B vs $5.83B target.
Ensign Group grows revenue about 14% a year, reaching $5.83 billion in 2026. Profit margins improve with operating income rising to $124.85 million in Q1 2026. The company repurchases stock to boost shareholder value. Management steadily increases net income, hitting nearly $100 million in Q1 2026.
Compliance concerns and short seller allegations may hurt revenue growth. Recent guidance cuts and a 16.6% price drop show risks. Acquisition growth and stock buybacks face uncertainty amid these challenges.
The price is about 4% below our fair value near $178, reflecting analysts' expectation of 14% revenue growth. Our view aligns with consensus but we note risks from compliance issues and guidance cuts.
Breaks if: Stock repurchase authorization is reduced below $40 million
Breaks if: Net income falls below $80.28 million in Q1 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable growth opportunity in the healthcare sector. The current thesis state is intact, supported by strong revenue and income growth, though it faces some near-term risks.
The market appears to have priced in a neutral valuation, indicating that expectations are not overly optimistic or pessimistic. There is a slight premium compared to peers, suggesting that the market recognizes ENSG's solid performance but does not expect significant outperformance.
Fundamentals are likely to continue improving, as management has consistently focused on revenue growth and operational efficiency. Recent financial performance has been strong, with significant increases in revenue and net income, although there is a low probability of missing future targets.
The thesis hinges on management's ability to maintain guidance and deliver on growth targets. Additionally, the performance of sector bellwethers and overall economic conditions, such as job growth, will be critical in shaping future outcomes.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read on the company. However, ongoing legal investigations threaten to impact investor confidence and operations.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Grow net income through revenue growth, operational improvements, and disciplined acquisitions.
Stated as a priority in 4 of last 4 quarters. GAAP net income increased from $80.3 million in 2025-Q1 to $99.7 million in 2026-Q2, an increase of 24.2%. Management's focus on revenue growth and operational improvements is delivering consistent net income growth.
“GAAP net income was $99.7 million for the quarter, an increase of 18.2% over the prior year quarter.”
“GAAP net income was $99.7 million for the quarter, an increase of 24.2% over the prior year quarter.”
“GAAP net income was $95.5 million for the quarter, an increase of 19.8% over the prior year quarter.”
“Strong financial performance reflects benefits of proven business model built on clinical excellence and local leadership.”
Breaks if: Operating income falls below $101.37 million in Q1 2026
Improve operating income through operational efficiencies and clinical excellence across facilities.
Stated as a priority in 4 of last 4 quarters. Operating income increased from $101.4 million in 2025-Q1 to $122.5 million in 2026-Q2, reflecting operational improvements and clinical excellence. Management's focus on operational efficiency and quality care is delivering improved profitability.
“Investments in clinical programs translate into superior quality outcomes and financial results.”
“Consistent financial performance reflects a relentless, patient-focused culture and operational excellence.”
“Record quarter and year with improved operating income driven by clinical excellence and operational stability.”
“Strong financial performance reflects benefits of proven business model built on clinical excellence and local leadership.”
Breaks if: Revenue falls below $5.06 billion in FY 2026
Continue to grow revenue through organic improvements and disciplined acquisitions across skilled nursing and senior living operations.
Stated as a priority in 4 of last 4 quarters. Consolidated revenue grew from $1.17 billion in 2025-Q3 to $1.44 billion in 2026-Q2, a 22.7% increase. Annual revenue guidance was raised twice in 2026, from $5.77-$5.84 billion to $5.87-$5.92 billion. Management is delivering consistent revenue growth through organic improvements and disciplined acquisitions.
“We continue to see strong demand across our portfolio, improving occupancy and skilled mix. We also continue to grow in a disciplined way through acquisitions.”
“Our local leaders continue to be examples of excellence as they earn trust through high-quality clinical outcomes and growth.”
“We are excited to report record quarter and year with growth in occupancy and skilled mix across our portfolio.”
“We continue to acquire new operations with significant long-term upside and expect to maintain a healthy pace of growth.”
In the next 1 to 3 years, ENSG's performance will depend on its execution and external economic factors. Not investment advice.